The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
 
Yu-Wei Chen
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Honoraria - Janssen
Consulting or Advisory Role - Deloitte
 
Lin Liu
No Relationships to Disclose
 
Minya Pu
No Relationships to Disclose
 
Samuel Pena
No Relationships to Disclose
 
Qian Qin
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Exelixis
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Hamid Emamekhoo
Consulting or Advisory Role - AVEO; Cardinal Health; Cardinal Health; Exelixis; Janssen Biotech; Seagen; Seagen
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Gilead Sciences; Immunomedics; Janssen; Pfizer/Astellas; Pfizer/Myovant; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Akash Patnaik
Stock and Other Ownership Interests - Gilead Sciences; Infinity Pharmaceuticals; Merck; Merck
Honoraria - Medscape; Prime Oncology
Consulting or Advisory Role - Curio Science; Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Laekna Health Care (Inst); Progenics (Inst); Xencor (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)